Correction of anemia in uremic mice by genetically modified peritoneal mesothelial cells  by Einbinder, Tom et al.
Kidney International, Vol. 63 (2003), pp. 2103–2112
Correction of anemia in uremic mice by genetically modified
peritoneal mesothelial cells
TOM EINBINDER, YUVAL SUFARO, IGOR YUSIM, GERARDO BYK, JUTTA PASSLICK-DEETJEN,
CIDIO CHAIMOVITZ, and AMOS DOUVDEVANI
Department of Nephrology and Department of Urology, Soroka University Medical Center, Ben-Gurion University, Beer-Sheva,
Israel; Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel; and Fresenius Medical Care, Bad Homburg, Germany
Correction of anemia in uremic mice by genetically modified neal dialysis (CAPD)-treated patients can be used as a
peritoneal mesothelial cells. vehicle for gene therapy. This was done using the eryth-
Background. During peritoneal dialysis, mesothelial cells be- ropoietin (EPO) as the target gene.come detached from the peritoneum and accumulate in the di-
The most prevalent approach for gene insertion ther-alysate. Our aim was to evaluate the potential of peritoneal efflu-
ent (PF)-derived human peritoneal mesothelial cells (HPMC) apy in humans is the ex vivo approach in which genetic
as target for gene therapy. We used erythropoietin (EPO) as our information is introduced into target cells that are re-
target gene. moved from the body and subsequently reimplanted.Methods. Various extracellular matrixes (ECM) were tested
Ideally, autologous target cells for ex vivo gene therapyfor optimal adhesion and growth of HPMC. The EPO gene
was introduced to mouse peritoneal mesothelial cells (MPMC) should be relatively easy to obtain and should inflict
and HPMC by transfection or retroviral transduction. EPO minimal trauma to the patient. The cells should be able
secretion from PMC was measured by enzyme-linked immuno- to express the gene once it is inserted and should besorbent assay (ELISA) and by the TF-1 cell proliferation assay.
easily engrafted back into the body [1].We performed intraperitoneal or intramuscular transplanta-
tions of the genetically modified cells into regular or 5/6 ne- In past studies, various genes have been introduced
phrectomized Balb/c mice and nude mice. Finally, we measured into immortalized mesothelial cell lines for gene therapy
serum EPO and hematocrit levels. model applications, such as thrombomodulin [2], growthResults. ECM-coated plates provided up to sixfold increase
hormone (GH) [3–5], 1-antitrypsin [3], and Lac Z [6].in the efficiency of PMC isolation from PF. Gelatin coated dishes
(20 g/cm2) were found optimal for isolation of PF-HPMC. Their expression was demonstrated in both tissue culture
RPR-120535 liposome was found to be best for PMC transduc- and animal models.
tion. In vitro studies showed EPO secretion from modified Since immortalized cell lines cannot be considered asHPMC over 6 months. Intraperitoneal transplantation aided
an option for gene therapy in humans due to their haz-with collagen matrix was the most effective. EPO, in MPMC
transplanted mice, was detected up to 3 weeks (peak at 13  ardous potential of developing malignancy, we chose to
1 mIU/mL), and anemia of uremic mice was corrected (35.3  use primary cell cultures. Others and we have demon-
0.9 mIU/mL to 41.9  1.1 mIU/mL). strated that mesothelial cells obtained from CAPD-Conclusion. PF-HPMC can be considered as an appropri-
treated renal failure patients can be isolated through aate target for gene therapy since these cells can be efficiently
relatively easy and noninvasive procedure [7]. Duringisolated, modified, and transplanted. Nevertheless, implanta-
tion techniques in the peritoneum should be directed at ob- peritoneal dialysis, large quantities of mesothelial cells
taining longer duration of transgene expression in vivo, and become detached from the peritoneum and accumulatemeans should be developed for enabling regulated expression
in the dialysate. These cells can be subsequently culturedof the gene.
and appear to retain in vitro most of their physiologic func-
tions. Di Paolo et al [8] successfully reimplanted omen-
The purpose of this study was to investigate whether tum-derived HPMC (OM-HPMC) into the peritoneal
peritoneal fluid–derived (PF) human peritoneal meso- cavity of patients on CAPD and repopulated the meso-
thelial cells (HPMC) of continuous ambulatory perito- thelial layer that had been damaged by peritonitis during
CAPD treatment. Peritoneally reimplanted genetically
Key words: erythropoietin, peritoneal dialysis, mesothelial cells. modified mesothelial cells may systematically deliver a
gene product by utilizing the rich vascularization of theReceived for publication September 15, 2002
peritoneum. Hence, we concluded that PF-HPMC is anand in revised form December 29, 2002
Accepted for publication January 27, 2003 excellent choice for gene therapy in our experiments.
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ure (ESRF) patients and in most cases is due endocrine MPMC. To prepare MPMC, peritoneum was removed
from eight newborn (2-week-old) Balb/c mice. Tissue dis-failure of the impaired kidney [9]. In recent years, gene
therapy for EPO insufficiency has been the subject of aggregation was performed as described for OM-HPMC.
The disaggregated tissue was suspended in 20 mL me-intense study [10]. Various studies demonstrated the in-
troduction of EPO into various cell types, including fi- dium, loaded in a 50 mL tube on a 10 mL histopaque
1077 (Sigma Chemical Co.) cushion and centrifuged forbroblasts [11], smooth muscle cells [12], keratinocytes
[13], myoblasts [14], and bone marrow mesenchymal cells 20 minutes (360 g) to remove tissue debris. Cells were
colleted from the cushion washed with phosphate-buf-[15]. Therefore, we chose to use EPO as the transgene
for our experiments with PMC. fered saline (PBS), suspended in 20 mL M199 medium
and seeded in a 75 cm2 flask (20 g/cm2 gelatin-coated).Our first step was to explore suitable techniques to
improve the yield and growth of PF-HPMC from patients Most experiments were preformed on cells from the sec-
ond passage.during CAPD. Then we investigated the ability to trans-
duce PMC with replication-deficient retrovirus contain- HPMC and MPMC characterization. Since the har-
vested cells had to be identified as mesothelial cells,ing the cDNA sequence of the human EPO gene. Finally,
we examined whether the EPO protein, secreted by im- samples of each HPMC (PF-HPMC or OM-HPMC) or
MPMC preparation were morphologically inspected forplanted genetically modified PMC, could correct anemia
in uremic mice. uniform appearance and for the presence of microvilli.
They were also inspected for the expression of vimentin
(antibody #V5255, Sigma Chemical Co.) and cytokera-
METHODS
tins (antibody #C1801, Sigma Chemical Co.), which are
Preparation of PMC characteristic of mesothelial cells, by indirect immuno
fluorecence [16]. The cultured cells were tested to beHPMC were obtained from the dialysate effluent of
CAPD patients or from a biopsy of omentum taken at negative for cells expressing CD68, a macrophage/mono-
cyte marker (patts-M-814; Dako, Copenhagen, Den-elective surgery (with informed consent of the patients)
[7, 16]. Mouse peritoneal mesothelial cells (MPMC) were mark) and for factor VIII, a marker of endothelial cells.
obtained from the peritoneum of Balb/c mouse.
Preparation of extracellular matrixHarvesting and culturing PF-HPMC. PF-HPMC were
(ECM)–coated platesobtained from the peritoneal effluent during initial wash-
ing cycles of the peritoneal cavity 1 or 2 weeks after in- To evaluate the effect of various matrices on HPMC
adhesion and growth, we coated 96-well plates with sevensertion of a Tenckhoff catheter. The infusion bag with
effluent was immersed in ice for 5 minutes and then hung dilutions (1:4 sequential dilutions in distilled water) of
gelatin (2% solution from bovine skin, initial concentra-up in a cold room for 1 hour. The initial 50 mL sediment
containing mesothelial cells was collected in a 50 mL tion 250 g/cm2), collagen type I (rat tail collagen, initial
concentration 29 g/cm2), fibronectin (FN) (initial con-tube and used for experiments or culturing.
The initial 50 mL sediment of the dialysate was seeded centration 11.5g/cm2), poly-d-lysine (PDL) (initial con-
centration 4.5g/cm2), and laminin (initial concentrationinto 20 g/cm2 gelatin precoated flasks or wells [gelatin
2% solution (bovine skin)] (Sigma Chemical Co., Reho- 11.5 g/cm2). All coating matrices were purchased from
Sigma Chemical Co. Coating was performed by fillingvot, Israel). Coating was done by dispersing diluted gela-
tin (75 L of 2% gelatin dissolved in 5 mL of distilled the plate-wells with one or more of the diluted materials
(14 L/well), followed by vacuum drying for 1 hour.water) in flasks, followed by vacuum drying and gas
sterilization. Cells were incubated overnight in an atmo-
HPMC adhesion assaysphere of 5% CO2 at 37C. Nonadherent cells were re-
moved by aspiration and two washes with Hank’s buffer In order to find optimal adhesion conditions, OM-
HPMC or PF-HPMC (104/well in 100 L medium) fromsalt solution (HBSS). HPMC were grown in M199 me-
dium containing 10% fetal calf serum (FCS), 2 mmol/L the second to the fourth passages were seeded onto
ECM-precoated 96-well plates and incubated at 37C forl-glutamine, 100 U/mL penicillin, 100 mg/mL streptomy-
cin, and Biogro 2 (all tissue culture reagents, including 1 hour. Following incubation, nonadherent cells were re-
moved by two washes with HBSS, and wells were refilledBiogro, were obtained from Biological Industries, Beth
Haemek, Israel). The cells were grown to confluence and with 100 L of M199 medium and incubated overnight.
Relative cell number was assayed by the colorimetricthen harvested by trypsin-ethylenediaminetetraacetic acid
(EDTA) to be reseeded in 1:3 dilutions on 75 cm2 flasks. XTT assay using a commercial kit (Biological Industries)
and quantitated enzyme-linked immunosorbent assayOM-HPMC. OM biopsies (2 to 5 cm2) were obtained
by abdominal surgery for and HPMC were isolated as (ELISA) reader. The XTT assay is based on the ability
of live cells to reduce tetrazolium salt (XTT) to orange-previously described [16]. Most experiments were pre-
formed on cells from the second to the fourth passage. colored compounds of formazan.
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Growth assay for PF-HPMC is much more effective than transfection. We generated
a retroviral vector produced from the amphotropic PT67To find the optimal matrix for isolation and growth
retroviral packaging cells (Clontech Laboratories, Inc.,of PF-HPMC, 200 L of dialysate sediment (prepared
Mountain View, CA, USA) This packaging cell line wasas described above) were seeded onto the ECM-pre-
made to express high titers of EPO retroviral vector.coated 96-well plates and incubated overnight at 37C.
The retroviral vector was generated by transduction ofThen, nonadherent cells were removed by two washes
the PT67 packaging cell line with an ecotropic retroviralwith HBSS and the wells were refilled with 100 L of
vector produced by the GP E86 packaging cell lineM199 medium and incubated for 7 days. At the end of
[19]. Following transduction, PT67 cells were selected forthe incubation period, relative cell number was evaluated
puromycin resistance (resistance encoded on the pBabe-by the XTT assay as described above.
EPO retroviral vector) by medium containing puromycin
(2 g/mL) (Sigma Chemical Co.). Puromycin-resistantConstruction of an EPO expressing vector
colonies were picked-up, expanded, and screened forWe have generated an EPO expression vector (pBabe-
their efficiency to produce infective particles (ampho-EPO) by cloning EPO cDNA into a plasmid containing
tropic retroviral vector). The latter was evaluated by theira retroviral expression vector. The human EPO cDNA
ability to produce puromycin-resistant colonies (CFU)(PifEPO) vector was kindly provided by Dr. T. Ohta
upon transduction of the Balb/c 3T3 fibroblast cell line.(Fujiaski Institute, Hayashibra Biochemical Labora-
The most effective amphotropic retroviral vector–pro-tories, Inc., Okayma, Japan) [17]. The pBabe-puromycin
ducing lines were extended and large volumes of the cellretroviral vector plasmid [18] was supplied by Dr.
supernatant containing the vector (1  106 CFU/mL)H. Land (Immunologic Pharmaceutical Corp., Cam-
were snap-frozen and kept at –70C in aliquots.bridge, MA, USA). The PifEPO polyadenylation signal
Retroviral transduction of HPMC and MPMC. To ob-was removed by cutting the cDNA insert and recloning
tain maximal transduction efficiency, we tested threeit into a new pBabe-puromycin vector. This vector was
transduction protocols using the following transductionused for liposomal transfection and for retroviral vector
facilitation reagents: (1) polybrene, (2) diethylaminoethylbuilding. For mock transfection and transduction, we
(DEAE) dextran, and (3) cationic liposome. In prelimi-
used the vector without the EPO insert.
nary experiments, all transduction methods were opti-
mized for HPMC before comparison. We tested poly-HPMC transfection
brene in concentrations of 1 to 16g/mL, DEAE dextran
We used commercial liposome Tfx 20 (Tfx, Promega, in concentrations of 0.5 to 10 mg/mL, and transduction
Madison, WI, USA) to introduce the pBabe-EPO to with the liposome RPR 120535 was tested in concentra-
HPMC. For transfection, HPMC were seeded in 24-well tions of 1 to 10 mol/L [20].
plates (104 cells/well). Following overnight incubation, For comparing the transduction methods, PF-HPMC
medium was removed, and the cells were incubated with were seeded in 12-well plates (5  104 cells/well) and
200 L of transfection medium per well for 1 hour. Then incubated overnight before transduction in the presence
1 mL of complete medium was added and cells were incu- of human epithelial growth factor (EGF 30 ng/mL) (Pe-
bated overnight. The transfection medium was prepared protech, Rocky Hill, NJ, USA). Since retroviruses inte-
by brief vortex of serum-free M199 medium, Tfx 20 (11.25 grate only to the genome of proliferating cells, EGF was
L/mL) and pBabe-EPO DNA (3.75 g/mL). After in- used prior, during, and 24 hours after transduction to
cubation for 15 minutes at room temperature, the trans- achieve maximal integration of the retroviral vector. Our
fection medium was added to the cells. Transfected cells data indicate that EGF improves retroviral integration
were maintained in complete M199 medium, which was efficiency up to 30% (data not shown). For polybrene-
replaced weekly. Supernatant was collected at various aided transduction, cell medium was replaced and incu-
intervals over a period of 6 months. At 24 hours prior bated overnight with 0.5 mL of retroviral medium con-
to collection, the medium was replaced. Cell number taining polybrene (4 g/mL) (Sigma Chemical Co.). For
following transfection was determined from two wells for DEAE dextran–aided transduction, medium was re-
each experiment 24 hours after transfection. No apparent moved from HPMC and cells were exposed for 1 minute
changes of the genetically modified cells morphology or to cold DEAE dextran solution (5.0 mg/mL) (Sigma
viability were observed. Chemical Co.). Then DEAE dextran solution was aspi-
rated, after which cells were washed three times with
HPMC and MPMC transduction prechilled HBSS and exposed to 0.5 mL of retroviral
Generation of the EPO-expressing retroviral vector. medium overnight. Liposome-aided transduction was
The efficiency of cell transfection, as described above, done by overnight exposure of HPMC or MPMC to
is relatively low, especially for primary culture of cells. retroviral medium containing liposome. This medium
was prepared just prior to treatment of the cells by shortTherefore, we employed retroviral transduction, which
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vortex of retroviral medium with RPR 120535 liposome 2 mm2 piece of Aviten was placed upon it. Then, 5 
106 transduced MPMC or HPMC (EPO production of(1 L/mL of 5 mmol/L solution) and incubation for 15
minutes at room temperature. 1000 mIU per 106 cells/day) suspended in 100 L PBS
were absorbed in the Aviten layer. The treated animalsFollowing transduction by the various protocols, trans-
duction medium was replaced with M199 complete me- were allowed to recover for 24 hours and were then fol-
lowed up for hematocrit and EPO levels using tail blooddium. Supernatants were collected at various intervals
over a period of 3 months; medium was replaced 24 hours samples (100 L) taken using hematocrit capillaries.
Since the transduced cells secreted human EPO, theprior to collection. Cell number following transduction
was determined on two wells for each experiment 24 transplanted Balb/c mice were treated by a daily injec-
tion of cyclosporin A (5 mg/kg) (Sandimune, Novartis,hours following transduction. No apparent changes in
cell morphology or viability were seen on the genetically Basel, Switzerland) to prevent immunologic reaction
against the grafted cells and the secreted human hor-modified cells.
mone. Intramuscular transplantation was performed.
Assessment of EPO secretion Under the same conditions, 5  106 transduced MPMC
or HPMC (EPO producion of 1000 mIU per 106 cells/EPO protein levels. The presence of human EPO in
sera and in the supernatants of genetically modified PMC day) suspended in 100 L PBS were injected into the
two quadriceps (50 L to each muscle). Hematocrit andwas analyzed by a commercial ELISA kit (R&D Sys-
tems, Minneapolis, MN, USA), with a sensitivity of serum EPO levels were followed, as described above.
0.6 mIU/mL and a detection range of 2.5 to 200 mIU/mL.
Statistical analysisEPO-biologic activity (TF-1 cell proliferation assay).
EPO biologic activity was analyzed using the EPO-sensi- Unless otherwise indicated data are presented as
mean  SE. Statistical analysis was performed by one-tive cell line TF-1 [21]. TF-1 cells were seeded in 96-well
plates (1  105 cells/well in 100 L of RPMI medium). way analysis of variance (ANOVA).
A total of 100L of HPMC and MPMC cell supernatants
collected for 24 hours or standards [0.01 to 10 IU/mL
RESULTS
recombinant human EPO (rhEPO), Eprex, Janssen-
Adhesion assayCilag, Berchem, Belgium] were added to each well. On
day 6, relative cell number was assayed using the XTT In order to increase the harvest of mesothelial cells
from peritoneal effluent, we initially tested if coating ofassay as described above.
culture dishes with various matrix agents increases the
Transplantation adhesion of HPMC compared to uncoated dishes. We
coated 96-well plates with various concentrations andIn preliminary experiments, we tested various meth-
ods to implant transduced PMC such as intraperitoneal various combinations of matrix agents and evaluated
the relative HPMC adhesion to the wells 1 hour afterinjection of autologous transduced MPMC to untreated
peritoneum, to peritoneum following the induction bac- incubation. In this set of experiments OM-HPMC or
PF-HPMC were isolated, cultured, and then assayed forterial peritonitis, and to peritoneum following mechani-
cal rubbing of mesothelial layer. Using these techniques, adhesion capacity. The results of the experiments with
PF-HPMC were similar to those with OM-HPMC and,transplantation efficiency proved to be very low. We there-
fore, tested the use of a collagen matrix (Aviten, Ethicon, therefore, for ease of presentation, the data were not
separated. The dose-dependent effects of different ma-Inc., Johnson & Johnson Company, New Brunswick, NJ,
USA) to bond the transduced cells on the peritoneum trix agents on HPMC adhesion are shown in Figure 1.
Collagen, gelatin, FN, laminin, and PDL all increasedand found this significantly more effective.
For transplantation of MPMC, we used 2-month-old HPMC adhesion. The most effective agents were colla-
gen, gelatin, and FN, having a more than fourfold maxi-Balb/c female mice. In some experiments uremia and
anemia was induced in Balb/c mice by 5/6 nephrectomy mal increased adhesion compared to the control; PDL
and laminin were less effective, increasing adhesion only[22]. After uremia was confirmed (3 to 4 weeks follow-
ing nephrectomy), the 5/6 nephrectomized mice were by twofold. All agents generally had a bell-shaped re-
sponse to the increase in concentration of the coatingtransplanted. For transplantation of HPMC, we used
2-month-old nude mice [23]. A week and 1 day before agent. In our experimental system, FN was the most
potent adhesion mediator, increasing adhesion fromtransplantation, tail blood was taken for measuring base-
line hematocrit levels. 1.5  0.02-fold at 2.81  103 g/cm2 concentration to
a peak of 6.11-  0.21-fold more than the control atMice were anesthetized using ketamine-rumpon cock-
tail (10 mL/kg). A 1 cm incision was made into the 2.88 g/cm2 concentration. Collagen and gelatin in-
creased adhesion from 3.22 0.22-fold and 2.74- 0.13-abdomen wall and the parietal peritoneum. The perito-
neum over the liver was dried with a sterile pad and a fold at 0.01 g/cm2 and 0.06 g/cm2 concentrations, re-
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Fig. 1. The effect of extracellular matrix (ECM) on human peritoneal mesothelial cells (HPMC) adhesion. To test the effect of ECM on the
adhesion of HPMC, 96-well plates were coated by vacuum drying of 1:4 sequential dilutions in distilled water of collagen (type I, initial concentration
29 g/cm2), gelatin (initial concentration 250 g/cm2), fibronectin (initial concentration 11.5 g/cm2), laminin (initial concentration 11.5 g/cm2),
poly-d-lysine (initial concentration 4.5 g/cm2), and combination of ECM reagents of the same concentration. Omentum (OM)-HPMC or peritoneal-
derived fluid (PF)-HPMC (104 cells/well) from the second to the fourth passage were seeded on precoated 96-well plates and incubated at 37C
for 1 hour. Following incubation, nonadherent cells were removed and adherent cells were incubated in medium overnight. Relative cell number
was assayed using the colorimetric XTT assay (adhesion index 1 was normalized for all experiments and is equal to adhesion to uncoated wells).
The figure represents the normalized results of seven unrelated experiments (four on OM-HPMC and three on PF-HPMC). Results are presented
as mean  SE.
spectively, up to a peak of 5.6-  0.17-fold and 4.5-  HPMC directly from peritoneal effluent (PF-HPMC).
0.25-fold at 1.81 g/cm2 and 62.5 g/cm2 concentrations, Peritoneal fluid sediments were distributed on coated
respectively. The peak adhesion seen in laminin- and 96-well plates and incubated overnight. Then, the perito-
PDL-coated wells was only 1.67- 0.44-fold and 2.16- neal fluid was replaced with fresh medium and the rela-
0.21-fold at 2.88 g/cm2 and 4.39  103 g/cm2 concen- tive cell growth was analyzed on day 7. The effects of dif-
trations, respectively. ferent concentrations of adhesion agents on PF-HPMC
In an additional set of experiments, we combined two growth are depicted in Figure 2. Similar to the effect
or three matrix agents and evaluated HPMC adhesion. on adhesion, collagen-, gelatin-, and FN-coated wells
The lower panel of Figure 1 shows the relative adhesion significantly improved the isolation and growth of PF-
of HPMC in descending concentrations of mixed adhe- HPMC compared to uncoated wells, while laminin had
sion factors (collagen gelatin, gelatin FN, collagen only a mild effect. PF-HPMC isolated and grown on
FN, gelatin  laminin, and gelatin  collagen  FN). collagen-, gelatin- and FN-coated wells produced a bell-
Improved HPMC adhesion was obtained by mixture- shaped response to increased matrix concentrations. FN
coated wells, as compared to uncoated wells. Compared had the greatest effect on PF-HPMC isolation and
to HPMC adhesion to one factor alone, HPMC peak growth. The minimal increase of growth was 1.5-fold at
adhesion did not increase on mixture-coated wells. Ad- 2.81  103 g/cm2 FN concentration, reaching a peak
hesion to descending mixture concentrations generally
of 4.86-fold at 0.72 g/cm2 concentration. The minimalhad a bell-like–shaped response. The best HPMC adhe-
increase of growth with collagen and gelatin was 1.38- sion was achieved with a mixture of collagen  gelatin
0.19-fold and 1.78-  0.15-fold at 7.1  103 g/cm2 andwith a peak adhesion of 5.57-  0.09-fold, as compared
0.06 g cm2, respectively, and the peak increase wasto uncoated dishes. A mixture of gelatin  laminin
4.78-  0.26-fold and 3.82-  0.26-fold at concentrationsyielded the least effective HPMC adhesion with a peak
of 1.81 g/cm2 and 62.5 g/cm2, respectively. The peakadhesion of 4.27-  0.16-fold.
effect of laminin was 1.43- 0.05-fold at a concentration
Isolation and growth of PF-HPMC on various of 0.18 g/cm2.
adhesion agents Various combinations of adhesion agents had no sig-
nificant advantage over the use of a single agent (Fig. 2).The aim of this set of experiments was to test if various
adhesion agents improved the isolation and growth of A combination of gelatin  collagen was found to be
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Fig. 2. Isolation and growth of peritoneal-derived fluid (PF) human peritoneal mesothelial cells (HPMC) on different extracellular matrix (ECM)
factors. To find the optimal matrix for isolation and growth of PF-HPMC, 50 mL sediments were collected from 1 L of effluent, and 200 L/well
were added to ECM-coated 96-well plates. The plates were incubated overnight, nonadherent cells were removed, and wells were refilled with
medium and incubated for 7 days. At the end of incubation, the relative cell number was evaluated by the XTT assay. Data were obtained from
seven unrelated experiments and results are presented as mean  SE. Samples of each PF-HPMC preparation were characterized for mesothelial
cell markers.
the most effective coating for isolation and growth of
PF-HPMC with a peak of 5.82-  0.2-fold greater than
growth in noncoated wells. In contrast, combinations of
laminin with gelatin or FN were less effective than either
gelatin or FN coating alone. Mixtures of gelatin, collagen,
and FN were less effective than coating with each agent
alone.
HPMC transfection
In order to show that HPMC are able to secrete biolog-
ically active EPO, cells were transfected with the pBabe-
EPO plasmid. Four primary cultures of each were trans-
fected with Tfx-20 at optimal conditions and EPO
production was measured monthly (Fig. 3). Peak EPO
secretion in all the lines appeared at the first point of Fig. 3. Erythropoietin (EPO) secretion from transfected human peri-
toneal mesothelial cells (HPMC). Omentum-HPMC (OM-HPMC) andmeasurement (day 1) with an exponential decline over
peritoneal-derived fluid HPMC (PF-HPMC) were transfected usingtime. All cell lines secreted detectable EPO levels at day
commercial Tfx 20 liposome with the EPO expression vector (EPO-
30. The OM-derived lines (OM-1 and OM-2) secreted pBabe), and EPO secretion over time was followed. EPO levels were
assayed using commercial enzyme-linked immmunosorbent assayhigher levels than the PF-derived cells (PF-1 and PF-2).
(ELISA) for human EPO. Following transfection at 24 hours, cells inAt day 90, both OM-derived cells secreted detectable
sample wells were counted, and EPO levels in the figure were adjustedEPO levels while no detectable levels were found in the for 106 cells. Results are presented as mean  SE of triplicates. The
supernatants of PF-HPMC. OM-1 secreted the highest figure shows four representative experiments out of eight independent
experiments performed on four OM lines, OM 1 () and OM 2 (),EPO levels. EPO production was followed for up to 6
and four PF lines, PF 1 () and PF 2 ().months. No further significant decline in EPO levels was
observed after days 30 to 40 and levels stabilized at day
90 up to day 170.
with the pBabe EPO retroviral vector (Fig. 4A). We
Retroviral transduction tested three reagents to facilitate HPMC transduction:
polybrene (standard protocol), DEAE dextran, and cat-In order to achieve a higher and more persistent ex-
pression of hEPO by HPMC, we transduced PF-HPMC ionic liposome RPR 120535. Following transduction,
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Table 1. EPO biologic activity
EPO activity
assay (TF-1) EPO ELISA Activity ratio
mIU/mL mIU/mL activity/protein
Mock 11 0 —
EPO-HPMC 1960240a 219.517 8.9
EPO-MPMC 550190 314.753 1.75
Abbreviations are: EPO, erythropoietin; ELISA, enzyme-linked immunosor-
bent assay; HPMC, human peritoneal mesothelial cells; MPMC, mouse peritoneal
mesothelial cells.
a Significantly more active than recombinant standard (Eprex), P  0.05
was far more efficient than any of the other methods.
No marked mortality and reduction in EPO production
was found in thawed transduced cells after freezing in
liquid nitrogen (data not shown). As shown in Figure
4B, compared to human cells, in transduced MPMC, the
increase in EPO production over time was less pro-
nounced. MPMC maintained a production of over1000
mIU/106 cells/24 hours EPO for 2 months.
EPO biologic activity measured by TF-1
cell proliferation
Supernatants of transduced PF-HPMC and MPMC
were collected. ELISA was used to evaluate EPO con-
centrations and its biologic activity was tested by prolif-
eration of the TF-1 leukemic cell line. As shown in Ta-
ble 1, supernatant from cells transduced with a mock
vector did not induce biologic activity. Both human and
mouse cells secreted biologically active EPO. EPO se-
creted from human cells was significantly more active
Fig. 4. Erythropoietin (EPO) secretion from transduced peritoneal than that secreted by mouse cells (8.9). The activityfluid-derived human peritoneal mesothelial cells (PF-HPMC) and
induced by rhEPO (Eprex), was used as a standard inmouse peritoneal mesothelial cells (MPMC). (A) PF-HPMC were trans-
duced with EPO-retroviral vector (106 CFU/mL) by three transduction this assay.
methods: EPO-polybrene (4g/mL) (), EPO-DEAE dextran (5 mg/mL)
(), and cationic RPR 120535 liposome (5 mol/L) ( ). Mock-lipo- EPO levels in transplanted micesome is (). (B) Mouse peritoneal mesothelial cells (MPMC) were
transduced with EPO-retroviral vector (106 CFU/mL) using the cationic Figure 5 shows the EPO levels in sera of mice trans-
RPR 120535 liposome (5 mol/L) (). For the control group, mock- planted with transduced PMC. Intraperitoneal injectionliposome () transduced the cells under the same conditions for that
of cells using collagen matrix (Aviten), was found to beof EPO-liposome with the same retroviral vector without the EPO
insert. EPO secretion was followed as indicated. Following transduction more effective than intramuscular injection of the human
at day 1, cells in sample wells were counted and EPO levels in the or mouse PMC. Following transplantation of either hu-figure were adjusted for 106 cells. Results are presented as mean  SE
man or mouse cells, we observed an exponential declineof triplicates. The figures show a representative experiment from three
independent experiments. over time in the production of EPO. Mice transplanted
with human cells reached 50% the sera EPO levels in
1 week (Fig. 5A) and with mouse cells in 2 weeks (Fig. 5B).
Since data on EPO levels of the uremic (5/6 neprectom-there was an increase in EPO secretion over time. Initial
ized mice) and nonuremic mice were not significantlymeasurements were 263, 396, and 622 mIU/L 106 cells/
different for ease of presentation the data are combined.24 hours, which rose up to 1108, 840, and 3544 mIU/L 
106 cells/24 hours at day 35 after transduction using poly-
Hematocrit levels in transplanted micebrene, DEAE dextran and cationic liposome, respec-
An increase in hematocrit was observed followingtively. A slight decline could be observed until the end
transplantation of mice with EPO-secreting MPMCof the experiment at day 90. Transduction efficiency per-
(Fig. 6). The increase in hematocrit reached significanceformed with polybrene and with DEAE dextran showed
at 1 week and remained elevated for an additional 2no significant differences. However, liposome-aided trans-
duction of HPMC (Fig. 4A) and MPMC (not shown) weeks. In the nonuremic mice (Fig. 6A), hematocrit was
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Fig. 6. Hematocrit levels in uremic and nonuremic mice transplanted
Fig. 5. Erythropoietin (EPO) sera levels in mice transplanted with with transduced mouse peritoneal mesothelial cells (MPMC). Non-
transduced peritoneal-derived fluid human peritoneal mesothelial cells uremic (A) and uremic (B) Balb/c mice (3 weeks after 5/6 nephrectomy)
(PF-HPMC) and mouse peritoneal mesothelial cells (MPMC) PF- were transplanted with transduced MPMC. Mice were bled for baseline
HPMC (A ) or MPMC (B ) were transduced with a mock or EPO retro- hematocrit levels a week before transplantation and during transplanta-
viral vector. For intraperitoneal transplantation, a piece of collagen tion. For all groups N 	 4. *P  0.05 compared to the mock group.
matrix (Aviten) was placed upon the liver peritoneum and cell (5  Symbols are: (), erythropoietin (EPO); (), mock.
106 cells in 100 L) were absorbed in it. Intramuscular transplantations
were performed by injection to the quadriceps (5  106 cells in 100 L).
Mice were bled at the indicated time point and sera were assayed
for EPO by enzyme-linked immunosorbent assay (ELISA). PF-HPMC
exchange and cultured for further genetic manipulation.were transplanted in nude mice and MPMC in Balb/c mice. N 	 8 for
the EPO-intraperitoneal (B) and N 	 4 for all other groups. *P  The culture technique we used significantly improved
0.05 compared to the intramuscular group. Symbols are: (), EPO- the yield of the dialysate-derived mesothelial cells. Ourintraperitoneal; (), EPO-intramuscular; (), mock-intraperitoneal.
hypothesis was that components of ECM might be bene-
ficial for harvesting PF-HPMC. First, we tested the effect
of various concentrations of collagen, gelatin, FN, lami-
nin, and PDL on HPMC-adhesion efficiency. As expected,elevated (41.3  0.3 to 49.1  0.6) and anemia was fully
all reagents served to increase the adhesion of HPMCcorrected in the uremic mice (Fig. 6B, 35.3  0.9 to
to the ECM-coated wells. These results can be explained41.9  1.1). Following transplantation of human cells to
by the favorable affinity of integrins to ECM compo-nude mice, the increase in hematocrit levels did not reach
nents. Similar to our findings, Leavesley, Stanley, andsignificance (data not shown).
Faull [24] and Betjes et al [25] have demonstrated that
HPMC express multiple functional receptors for ECM
DISCUSSION proteins, migrate efficiently on and toward them, and
Our results strongly support the notion that dialysate- adhere better to collagen and FN than to laminin. In the
derived human mesothelial cells are a potentially useful second set of experiments, we showed improved out-
tool for gene therapy. We demonstrated that these cells growth of PF-HPMC harvested directly from the dialysis
bag and cultured on ECM-coated plates in comparisoncan be collected from the effluent of peritoneal dialysis
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to ECM-free culture plates. Outgrow efficiency of PF- that transduced human mesothelial cells can be success-
HPMC on coated dishes was in accord with adhesion fully implanted in the peritoneal cavity of immune-com-
effectiveness. These findings confirmed that ECM bind- promised nude mice, and secrete detectable amounts of
ing plays a major role in harvesting and culturing of the gene product in the blood stream of these animals.
PF-HPMC. Collagen, gelatin, and FN were more effi- Transplantation of autologous murine cells to normal
cient than the other agents and there was no significant Balb/c mice maintained EPO expression by these cells
advantage to combinations of ECM agents. For large- for a longer period of time (EPO could be detected up to
scale isolation of PF-HPMC, we used gelatin for coating 3 weeks after transplantation). Transplanted EPO-pro-
since it is less expensive than collagen and FN and pro- ducing MPMC corrected the anemia of uremic mice and
duces similar results. significantly increased hematocrit levels in the nonure-
The access to the peritoneal cavity through an indwell- mic mice. The increase in hematocrit levels in these mice
ing catheter makes HPMC a relatively easy target for was in accord with EPO levels. The fact that hormone
ex vivo gene therapy. Therefore, as a first step in devel- produced by the genetically modified cell was biologi-
oping a genetic treatment, we tested whether PF-HPMC cally active was further confirmed by the proliferation of
are capable of ex vivo genetic manipulation. Retroviral TF-1 cells in the presence of supernatants of these cells.
transduction was found significantly more efficient than It is clear that for therapeutic use a regulatory system
transfection for introducing EPO into the mesothelial must be included in the promoter of the expression vec-
cells. In contrast to the exponential decline in EPO secre- tor to avoid overproduction of the hormone. Efforts in
tion seen in the transfected cells following transduction that direction have been made by Sommer et al [31] who
with the retroviral vector, we observed an increase in demonstrated doxycycline-regulated secretion of EPO
EPO secretion over time. The increment in EPO secre- by encapsulated myoblasts implanted subcutaneously into
tion is attributed to the proliferation of EPO-expressing mice [31]. By a similar implantation technique, Rinsch
cells in which most of the retroviral vector was integrated et al [32] demonstrated that oxygen regulated EPO ex-
into the genomic DNA. The genetically modified cells pression under the control of the hypoxia responsive
were viable and active after freezing in liquid nitrogen.
element of phosphoglycerate kinase promoter in my-
Therefore, implantation time could be set according to
oblasts. The latter work closely resembles physiologicthe needs and the physiologic condition of the patients.
regulation under which endogenic EPO is expressed [33].Transduction using a cationic lipid was by far more
In contrast to the long-term secretion of EPO in vitroeffective than transduction using polybrene or DEAE
by PF-HPMC and MPMC, in vivo EPO production wasdextran, which is consistent with previously reported
limited to several weeks. Osada et al [34] have injecteddata [26, 27]. The cationic lipid we used for DNA delivery
intraperitoneally an adenoviral vector to introduce thewas RPR 120535, a lipopolyamine that has been exten-
human EPO gene to PMC in a mouse model of polycysticsively studied by Byk et al [20] and Pitard et al [28],
kidney disease. Similar to our findings, the expressionand was used previously for enhancement of adenovirus
of human EPO and the correction of anemia were limitedinfections [29]. Although the cell penetration mechanism
to several weeks [34]. The mechanism of short-term func-of adenolipofection has been extensively studied by Fas-
tion of transduced mesothelial cells needs further clarifi-bender et al [30], to date no data are available on the
cation. Possible explanations for the decrease in EPOmechanistic aspects of cell penetration of retroviral/
production include shut-off of the retroviral promoter,cationic lipid formulations.
as previously described by Palmer et al [35] and GerrardSeveral reports have described implantation of meso-
et al [36], desquamation of the implanted cells, or anthelial cells into the peritoneum of experimental animals.
immune reaction against the human hormone, as pre-For example, Murphy et al demonstrated the production
viously demonstrated by Regulier et al [37].of human GH in athymic mice for several weeks after
the implantation of adenoviral transduced HPMC [4].
It was also shown that rats implanted with genetically
CONCLUSIONmodified mesothelial cells expressed 
-GAL or human
We have shown that harvesting mesothelial cells fromGH for up to 3 months [5, 6]. Di Paolo et al [8] demon-
peritoneal effluent can be improved significantly by astrated the feasibility of implanting HPMC in humans by
simple procedure using ECM-coated cell culture dishes.injecting autologous HPMC as a suspension and showed
We have demonstrated that PF-HPMC and MPMC trans-that they adhere to areas of denuded peritoneum in CAPD-
duced with a retroviral vector are capable of long-termtreated patients. After testing various transplantation
secretion of EPO. Importantly, we prove that geneticallytechniques based on peritoneal denudation, we found it
modified PMC can fully correct anemia in uremic mice.more efficient to affix the genetically modified cells onto
Therefore, PF-HPMC can be considered as an appro-the peritoneum using collagen matrix (Aviten). At this
critical stage of the study, we were able to demonstrate priate target for gene therapy.
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